ЧАБЕР Джон (US),КИДОНИУС Агис (US),КУЗМА Петр (US)
申请号：
RU2010126615/15
公开号：
RU2010126615A
申请日:
2008.11.26
申请国别(地区):
RU
年份:
2012
代理人:
摘要：
1. A pharmaceutical composition comprising an effective amount of valrubicin and dimethyl sulfoxide in an intravesical dosage form. ! 2. The pharmaceutical composition according to claim 1, where the effective amount of valrubicin is about 5-100 mg / ml, about 10-90 mg / ml, about 15-80 mg / ml, about 20-70 mg / ml, about 25-70 mg / ml, about 30-60 mg / ml, about 35-50 mg / ml or about 35-45 mg / ml. ! 3. The pharmaceutical composition according to claim 1, additionally containing one or more chemical penetration enhancers selected from the group consisting of: ethanol, isopropanol, dimethylacetamide, dimethylformamide, decylmethyl sulfoxide, 2-pyrrolidone, N-ethyl-2-pyrrolidone, capric acid, linoleic acid, urea, sodium dodecyl sulfate, sodium lauryl sulfate, and mixtures of two or more of these compounds. ! 4. The pharmaceutical composition according to claim 1, where an effective amount of valrubicin and dimethyl sulfoxide is sufficient for the treatment of bladder cancer. ! 5. The pharmaceutical composition according to claim 1, containing a substance for opening contacts. ! 6. The pharmaceutical composition according to claim 5, where the substance for opening contacts is selected from the group consisting of: trimethylchitosan, mono-N-carboxymethylchitosan, N-diethylmethylchitosan, sodium capric acid, cytochalazine B, IL-I, polycarbophil, carbopol 934P, N- sulfate-N, O-carboxymethylchitosan, Zonula occludens toxin, 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine and mixtures of any two or more of these compounds. ! 7. The pharmaceutical composition according to claim 5, where the amount of substance for opening contacts is about 1-15 wt.% By volume of the dosage form. ! 8. The pharmaceutical composition according to claim 1, containing polyethoxylated castor oil. ! 9. Fa1. Фармацевтическая композиция, содержащая эффективное количество валрубицина и диметилсульфоксида во внутрипузырной дозированной форме. ! 2. Фармацевтическая композиция по п.1, где эффекти
